Navigation Links
Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients
Date:9/22/2010

onstrates Positive Response in Rheumatoid Arthritis Patients  

LONDON and SAN FRANCISCO, September 22, 2010 /PRNewswire-FirstCall/ --

- Phase II Study Published in the New England Journal of Medicine

AstraZeneca's (LSE: AZN) new oral syk inhibitor, fostamatinib (R788), recently in-licensed from Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), significantly improved outcomes of patients with rheumatoid arthritis (RA) who responded inadequately to ongoing treatment with methotrexate (MTX), according to phase II study data published in The New England Journal of Medicine today.

In the six-month phase IIb study completed by Rigel, known as TASKi2, 67% of patients taking fostamatinib 100mg twice daily achieved the primary efficacy endpoint (ACR 20)* at six months, which was significantly higher than placebo. Thirty-six percent of patients achieved an ACR 20 response after just one week. Speed of onset may be an important factor in RA because permanent joint damage can occur when the disease is active. The most common adverse events included diarrhea and upper respiratory infection.

"In this study, we saw a significant clinical benefit in this rheumatoid arthritis population and a manageable safety profile," said Mark C. Genovese, Division of Rheumatology, Stanford University, Palo Alto, CA. "Based on the data, further study of fostamatinib as an oral agent for the treatment of patients with rheumatoid arthritis is certainly warranted."

Patients in the study had active RA despite treatment with MTX alone, and were given either fostamatinib 100mg twice daily (bid), fostamatinib 150mg once daily (qd), or placebo. Significant clinical benefits were reported in both fostamatinib groups in the key efficacy endpoints of the American College of Rheumatology (ACR) patient assessment criteria and Disease Activity Score (DAS) 28** remission criteria.

After six months: - The ACR 20 response was achieved by significantly mo
'/>"/>

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
2. More Evidence Published That Epidemics of Childhood Obesity, Type 2 Diabetes and Metabolic Syndrome are Linked to Immunization
3. Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
4. Wound Management Technologies, Inc. Announces a Published Case Study
5. Technique for Creating Authentic Rat Embryonic Stem Cells Published in Cell
6. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
7. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
8. Universal Bioenergy, Inc. Expressly Disclaims Any Responsibility for the Content, Accuracy of Information, and Quality of Information Regarding Universal Published by Any Third-Party and Being Disseminated on the Internet
9. International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
10. Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth
11. Life sticks: UC San Diego bioengineers sticky insights published in journal Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Bill Jacobs Automotive, a group of car dealerships headquartered in ... Heartland Blood Center and offering free oil change coupons for ... Saturday, Jan. 18 at the Bill Jacobs Cadillac and Chevrolet ... http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill Jacobs Auto ...
(Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal ... been selected by Buffalo BioBlower Technologies LLC ("B3") as ... SBIR Phase 2 award from the Army Corps of ... system that kills all biological contaminants and destroys VOCs ...
(Date:1/15/2014)... 2014 Cynvenio, a cancer diagnostics company ... genomic analysis of tumor cells in the bloodstream, today ... cancer decision support application powered by CollabRx, Inc. ... genomic test, Therapy Finder will provide breast cancer patients ...
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health , ... change technology, today announces that EmblemHealth , the ... wellness company, is now providing the RedBrick Compass health ... program, to all of its members. EmblemHealth is among ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3
... Session Highlights New Small Molecule Drug ... ... Inc.,(Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing,therapeutics for the ... and mechanism of action data for,its selective kinase inhibitor, ENMD-2076. On ...
... (Nasdaq: IMRX ) today announced that it received ... that for the last 30,consecutive business days, the bid ... share. As a result, the company fails to comply ... forth in,Marketplace Rule 4310(c)(4)., In accordance with Marketplace ...
... SGN ) has confirmed that it has filed ... Officer, Dr. Lowell T. Harmison, has,scheduled a webcast on ... Harmison stated: "Now that Signalife has closed filing the,company,s ... I am pleased to provide direction on new contracts, ...
Cached Biology Technology:EntreMed's Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session 2EntreMed's Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session 3ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQ's Minimum Bid Price Requirement 2Signalife Announces Webcast 2Signalife Announces Webcast 3
(Date:7/9/2014)... can alleviate the symptoms of Alzheimer,s disease, ... and effectively scavenge amyloid beta peptide in ... reduced and eliminated Aβ deposition in an ... significantly improved behavioral and cognitive impairment. Dr. ... Hospital of China Medical University, China immunized ...
(Date:7/9/2014)... cancer patients with high levels of vitamin D in their ... shows. , Patients with the highest levels of vitamin ... with the lowest levels, the findings reveal. , The study ... D in bowel cancer patients after their diagnosis which ... from dietary sources with their long term survival prospects. ...
(Date:7/9/2014)... first make a copy of its DNA, a fundamental step ... times a day in the human body. While scientists have ... to replicate DNAthe enzymes that unzip the double-stranded DNA and ... how the process works. , Now, researchers at Rockefeller University ... on at the "replication fork"the point where DNA is split ...
Breaking Biology News(10 mins):Rockefeller scientists first to reconstitute the DNA 'replication fork' 2Rockefeller scientists first to reconstitute the DNA 'replication fork' 3Rockefeller scientists first to reconstitute the DNA 'replication fork' 4
... German . It would appear reasonable to assume ... blueprints. However, scientists from the Max Planck Institute for Developmental ... team have now decoded, for the first time, the entire ... a close relative of the thale cress ( Arabidopsis thaliana ...
... at the Keck School of Medicine of the University ... the first time that the human placenta plays an ... new treatment strategies that could mitigate health impacts such ... findings, conducted with researchers from Vanderbilt University as part ...
... , Berkeley In a new study suggesting pesticides ... researchers at the University of California, Berkeley,s School of Public ... widely used on food crops is related to lower ... that every tenfold increase in measures of organophosphates detected during ...
Cached Biology News:Evolution can cause a rapid reduction in genome size 2Evolution can cause a rapid reduction in genome size 3USC research shows critical role of placenta in brain development 2Prenatal pesticide exposure tied to lower IQ in children 2Prenatal pesticide exposure tied to lower IQ in children 3Prenatal pesticide exposure tied to lower IQ in children 4
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
...
... Designed for serial preparation ... fractions including cytosol/particulate/cytoskeleton/nuclear fractions ... these fractions can directly ... assays such as 2-D ...
Wheat Germ Agglutinin (WGA) PS SPA Imaging Bead, 2 g. Category: Leadseeker Beads....
Biology Products: